CLDN3 and colitis: Moreover, in the present study, we found that treated with CXCR4 antagonist AMD3100 significantly promoted colonic claudin-1, claudin-3, claudin-5, claudin-7 and claudin-8 expressions, and also decreased colonic claudin-2 in colitis mice.